Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266643 · ClinicalTrials.gov registry record · Phase 4
Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 205
- Enrollment target
NCT00266643 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 205 participants.
The verdict
NCT00266643, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 205 participants
- Enrollment target
Study Summary
This study is to compare the tolerability of different methods for switching from another medication to duloxetine for the management of diabetic nerve pain. The primary objective is to compare the most gradual method with the most abrupt method, to see if they have different tolerability.
Interventions
- DRUG duloxetine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00266643
The ClinicalTrials.gov registry entry for NCT00266643 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which duloxetine hydrochloride is the first listed.
NCT00266643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00266643 about?
NCT00266643 is a clinical study titled "Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain". This study is to compare the tolerability of different methods for switching from another medication to duloxetine for the management of diabetic nerve pain. The primary objective is to compare the most gradual method with the most abrupt method, to see if they have different tolerability.
What is the current status of trial NCT00266643?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 205 participants. The study started on 2005-12. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00266643?
The interventions under investigation include: duloxetine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00266643?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.